"My job as your commissioner is to be your advocate and to fight for you. If you don't like it, we can get rid of it, but usually everybody loves money. The pilot program is intended to address growing bottlenecks in the pharmaceutical approval process by speeding up summaries and information gathering-all while maintaining, the FDA insists, the same level of scientific reviews as before."
"The program intends to reward review staff for efficiency and excellence, but it won't change review criteria, evidentiary thresholds, or quality safeguards. FDA reviewers will continue to apply the same gold-standard scientific integrity and independence to every application without compromising patient safety and public health."
The FDA has launched the 'Reviewer Recognition and Excellence' pilot program offering performance-based cash bonuses to staff who complete drug reviews ahead of schedule. This initiative addresses productivity challenges and employee retention, as the agency has lost approximately 20% of its workforce since Trump's second term began. Commissioner Marty Makary emphasized the program aims to reduce bottlenecks in pharmaceutical approval by accelerating summaries and information gathering. The FDA maintains that bonuses will not alter review criteria, evidentiary thresholds, or quality safeguards, ensuring scientific integrity remains unchanged. Quarterly payments are scheduled to begin in August, with the agency reiterating that reviewers will continue applying gold-standard scientific standards without compromising patient safety.
#fda-drug-approval-process #performance-based-incentives #pharmaceutical-regulation #employee-retention #regulatory-efficiency
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]